Oral Bacteria Drive Inflammatory Bowel Disease Through Gut-Mouth Connection

This minireview synthesizes emerging evidence that the oral microbiome, traditionally studied only in dental contexts, plays a significant role in inflammatory bowel disease (IBD) pathogenesis. The research matters because IBD affects millions globally with unclear causes, and current treatments often fail to achieve sustained remission.

The authors analyzed multiple studies showing that specific oral bacteria become enriched in IBD patients' intestines. Key pathogenic species include Fusobacterium nucleatum, Campylobacter concisus, and Veillonella species, which can breach the oral-gut barrier and colonize intestinal tissues. In treatment-naive pediatric CD patients, these oral bacteria were found in both mucosal biopsies and stool samples, with Fusobacterium being twice as abundant in severe UC cases.

The mechanism involves shared inflammatory pathways between periodontal disease and IBD. Both conditions exhibit overlapping immune dysfunction including increased cytokine production (IL-1, IL-6, TNF-α), neutrophil defects, and oxidative stress. Oral dysbiosis triggers systemic inflammation through bacterial translocation, immune modulation, and chronic cytokine release that can perpetuate intestinal inflammation.

Clinically, the research reveals bidirectional relationships: CD patients have increased periodontitis risk, while periodontal disease correlates with UC flares. Salivary inflammatory markers are elevated in IBD patients at baseline, suggesting oral inflammation precedes or accompanies intestinal disease activity.

The implications are significant for IBD management. The findings suggest that comprehensive oral health interventions—including improved dental hygiene, periodontal therapy, and potentially oral probiotics—could serve as novel adjunct treatments. This represents a paradigm shift toward more holistic IBD care that addresses the oral-gut axis.

However, limitations include the observational nature of most studies and unclear causality directions. More randomized controlled trials are needed to establish whether oral interventions can meaningfully improve IBD outcomes and determine optimal treatment protocols.